Perampanel · Fycompa

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • Use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) and tonic-clonic seizures in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs
Product first approved 2016PMDA
EU
  • Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.
Product first approved 2012EMA
CA
  • FYCOMPA (perampanel) tablets are indicated as: • adjunctive therapy in the management of partial-onset seizures in patients 7 years of age and older who are not satisfactorily controlled with conventional therapy. • adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients 12 years of age and older with epilepsy, who are not satisfactorily controlled with conventional therapy.
Health Canada

Development in Parkinson's Disease stopped for reasons the sponsor has not stated. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Epilepsy
NCT04309721 · Assistance Publique - Hôpitaux de Paris
2022-11-02 – 2023-11-13 · Epilepticus; Status, Focal Motor
What this study did
NCT02834793 · Eisai Inc.
2016-12-13 – 2021-07-19 · Lennox-Gastaut Syndrome (LGS)
What this study did
Focal Onset Seizures
Primary Generalized Tonic-Clonic Seizures
Other / comorbidity
NCT00360308 · Eisai Limited
2006-11 – 2008-04 · Parkinson's Disease
What this study did
NCT00360412 · Eisai Inc.
2006-10 – 2008-04 · Parkinson's Disease
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT00592904 · Eisai Inc.
2008-01 – 2011-07 · Neuralgia
What this study did
NCT00505284 · Eisai Inc.
2007-06 – 2008-07 · Diabetic Neuropathy
What this study did
Phase 2 (25)
Epilepsy
NCT06401707 · University of California, San Francisco
2024-05-20 – 2027-10-20 · Heart Arrest, Seizures, Status Epilepticus
What this study did
NCT02914314 · Eisai Inc.
2017-02-20 – 2023-04-25 · Epilepsy
What this study did
NCT03754582 · Eisai Co., Ltd.
2018-11-27 – 2019-12-10 · Epilepsy, Seizures
What this study did
NCT00903786 · Eisai Co., Ltd.
2009-06-17 – 2016-10-31 · Refractory Partial Seizures
What this study did
NCT00368472 · Eisai Inc.
2006-10 – 2014-07 · Epilepsy
What this study did
NCT00849212 · Eisai Co., Ltd.
2009-04 – 2009-11 · Refractory Partial Seizures
What this study did
NCT00416195 · Eisai Co., Ltd.
2006-12 – 2008-03 · Epilepsy
What this study did
NCT00144690 · Eisai Inc.
2005-03 – 2007-02 · Epilepsy
What this study did
NCT03780907 · Eisai Co., Ltd.
2003-02-14 – 2003-08-06 · Epilepsy
What this study did
Focal Onset Seizures
NCT04015141 · Eisai Inc.
2019-05-31 – 2027-12-23 · Pediatric Epileptic Syndrome, Partial-onset Seizures
What this study did
Other / comorbidity
NCT05786066 · Yale University
2023-04-03 – 2033-03 · Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
What this study did
NCT03377309 · American University of Beirut Medical Center
2019-12-01 – 2021-07-01 · Amyotrophic Lateral Sclerosis
What this study did
NCT03019419 · Tokyo Medical University
2017-04-24 – 2020-12-23 · ALS
What this study did
NCT02668146 · VA Greater Los Angeles Healthcare System
2015-10 – 2017-06 · Essential Tremor
What this study did
NCT02511873 · PNA Center for Neurological Research
2016-01 – 2016-12 · Neuropathy, Small Fiber
What this study did
NCT00566462 · Eisai Inc.
2007-10 – 2008-12-01 · Parkinson's Disease
What this study did
NCT01634360 · Eisai Inc.
2004-11 – 2008-06 · Parkinson's Disease
What this study did
NCT00427011 · Eisai Inc.
2007-02 – 2008-04 · Parkinson's Disease
What this study did
NCT00154063 · Eisai Inc.
2005-01 – 2006-06 · Migraine Prophylaxis
What this study did
Phase 1/2 (4)
Epilepsy
NCT04497142 · Dana-Farber Cancer Institute
2020-11-05 – 2023-05-16 · Glioma, Malignant, Surgery, Seizures
What this study did
Other / comorbidity
NCT02120365 · Virginia Commonwealth University
2019-06-01 – 2022-02-16 · Alcoholism
What this study did
NCT04502589 · Virginia Commonwealth University
2020-10-15 – 2021-08-11 · Alcohol Disorders
What this study did
NCT02131467 · University Health Network, Toronto
2017-09-01 – 2020-02-28 · Cervical Dystonia
What this study did
Phase 1 (16)
Epilepsy
NCT01209858 · Eisai Inc.
2010-03 – 2010-10 · Partial Onset Epilepsy
What this study did
NCT01240187 · Eisai Inc.
2010-06 – 2010-09 · Partial Onset Epilepsy
What this study did
Other / comorbidity
NCT05915013 · Yale University
2023-09-07 – 2032-12 · Depressive Disorder, Major, Post Traumatic Stress Disorder
What this study did
NCT07284069 · Aarhus University Hospital
2026-03-01 – 2028-11-01 · Glioblastoma
What this study did
NCT06969963 · Aya Mohammed Abdel Magid Abdel Hamid
2024-03-07 – 2024-07-23 · Bioequivalence Study in Healthy Subjects
What this study did
NCT03367533 · Yale University
2018-11-29 – 2022-07-08 · Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder
What this study did
NCT03793868 · Mayo Clinic
2018-12-04 – 2020-09-01 · Amyotrophic Lateral Sclerosis
What this study did
NCT03424564 · Eisai Co., Ltd.
2018-03-20 – 2018-05-25 · Healthy Subjects
What this study did
NCT03399734 · Eisai Co., Ltd.
2017-12-18 – 2018-03-09 · Healthy Participants
What this study did
NCT02116907 · Eisai Inc.
2014-05 – 2014-09 · Healthy Subjects
What this study did
NCT02020486 · Eisai Co., Ltd.
2013-12 – 2014-03 · Healthy
What this study did
NCT01531920 · Eisai Limited
2010-05 – 2011-04 · Central Nervous System
What this study did
NCT01396577 · Eisai Inc.
2010-12 – 2011-04 · Healthy
What this study did
Phase 4 (14)
Epilepsy
NCT05684978 · Wayne State University
2025-10-10 – 2025-10-10 · Refractory Status Epilepticus
What this study did
NCT05201703 · University of Florida
2022-03-09 – 2023-12-15 · Catamenial Epilepsy
What this study did
NCT04417907 · Kimford Jay Meador
2021-10-20 – 2023-05-01 · Epilepsy
What this study did
NCT04118829 · Carilion Clinic
2019-11-01 – 2023-03 · Epilepsy, Seizures
What this study did
NCT03457129 · University of Arizona
2018-04-18 – 2021-12-15 · Epilepsy
What this study did
NCT02900755 · Seoul National University Hospital
2016-12 – 2020-11-20 · Electroencephalography
What this study did
Focal Onset Seizures
NCT04650204 · Mayo Clinic
2020-12-04 – 2023-04-30 · Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
What this study did
NCT02727101 · Mid-Atlantic Epilepsy and Sleep Center, LLC
2015-11 – 2017-07 · Epilepsy
What this study did
NCT02220972 · Eisai Inc.
2015-03 – 2016-08 · Epilepsy, Partial
What this study did
Primary Generalized Tonic-Clonic Seizures
NCT03288129 · Eisai Inc.
2017-08-23 – 2021-04-27 · Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
What this study did
Other / comorbidity
NCT03653741 · Weill Medical College of Cornell University
2018-10-01 – 2021-11-29 · Healthy
What this study did
NCT02363933 · Duke University
2015-04-07 – 2017-04-10 · Brain Tumor, Primary
What this study did
Early phase / not applicable (3)
Epilepsy
NCT03636958 · Assistance Publique Hopitaux De Marseille
2021-02-15 – 2026-12-01 · Refractory Epilepsy
What this study did
NCT04858841 · National Cheng Kung University
2020-08-01 – 2023-07-31 · Middle Cerebral Artery Stroke
What this study did
Other / comorbidity
NCT03020797 · Stony Brook University
2017-01-12 – 2023-02-08 · Amyotrophic Lateral Sclerosis
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (2)
Epilepsy
NCT06450236 · Humanis Saglık Anonim Sirketi
2023-11-22 – 2024-02-06 · Epilepsy
What this study did
NCT06450223 · Humanis Saglık Anonim Sirketi
2023-09-14 – 2023-12-05 · Epilepsy
What this study did

Competitive landscape

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Perampanel (Fycompa): this drugApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fycompa (Perampanel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 2EpilepsyActive not recruiting
Est. primary completion 2027-04-06 · NCT04015141 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2EpilepsyRecruiting
Est. primary completion 2027-05-20 · NCT06401707 · CT.gov ↗
What to watch
2028 (1)
November 2028 (1)
Phase 1GlioblastomaRecruiting
Est. primary completion 2028-11-01 · NCT07284069 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 1Depressive Disorder, Major, Post Traumatic Stress DisorderRecruiting
Est. primary completion 2032-12 · NCT05915013 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 2Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal IdeationRecruiting
Est. primary completion 2033-03 · NCT05786066 · CT.gov ↗
What to watch

See the full readout calendar ↗